Figure 1.

The median and interquartile range of mRS. The median mRS significantly decreased from 3.5 (interquartile range, 3–4) before rituximab treatment to 0.5 (interquartile range, 0–1) at the last follow-up (before patient 3 and patient 6 had severe infectious adverse events) (P = 0.0201).